Mr. Rene Goehrum reports

BIOSYENT RELEASES Q4 AND FULL YEAR 2013 RESULTS: FULL YEAR SALES INCREASE 55%, NET INCOME UP 25%, 3 YEAR CAGR 67%, Q4 SALES INCREASE 61%

BioSyent Inc. released today a summary of its fiscal 2013 and fourth-quarter financial results. Key highlights include:

• Full-year 2013 sales of $7,799,426 increased by 55 per cent against 2012.
• Revenue has grown at a compound annual growth rate (CAGR) of 67 per cent over the last three years.
• Full-year 2013 pharmaceutical sales of $6,969,031 increased by 63 per cent against 2012.
• The company has had 17 consecutive quarters of continued pharmaceutical sales growth.
• Two thousand thirteen net income before tax of $2,452,840 increased year over year by 75 per cent.
• Two thousand thirteen tax expense (net of deferred tax credit) was $524,812 against ($142,195) in 2012.
• Net income after tax of $1,928,028 increased by 25 per cent against 2012.
• Two thousand thirteen basic earnings per share were 14 cents; fully diluted earnings per share were 13 cents.
• Cash generation in 2013 of $2,065,082 was 64 per cent higher than 2012.
• The company ended 2013 with $4,405,910 in working capital, of which cash was $4,381,137.
• The company remains debt free and has an unutilized operating line of credit with Royal Bank of Canada.
• The company was selected as a TSX Venture 50 top performer for three consecutive years -- 2012, 2013 and 2014.
• The company was named as one of Canada's fastest-growing companies in the Profit 500 rankings for 2013.
• Two new products were submitted to Health Canada, awaiting marketing approval.
• Prelaunch activity for a new women's health product has begun -- launch is planned for second quarter of 2014.
• Prelaunch activity for a new gastrointestinal health product has begun -- launch is planned for fourth quarter of 2014.

Total sales for fourth-quarter 2013 of $2,142,835 were 61 per cent higher compared with $1,327,953 in the corresponding prior-year period. On a full-year basis, sales in 2013 of $7,799,426 were 55 per cent higher than the previous-year sales $5,024,154.

Income before tax for fourth-quarter 2013 was $619,124, which was 71 per cent higher than $361,237 in fourth-quarter 2012. Net income before tax for full year 2013 was $2,452,840, an increase of 75 per cent over the corresponding prior-year period.

The company recognized a deferred tax credit of $232,199 in the fourth quarter of 2012. The company further recognized a deferred tax credit of $123,332 in the fourth quarter of 2013. These deferred tax credits pertain to the full years of 2012 and 2013. The increase of net income after tax in the fourth quarter of 2013 is 59 per cent over the fourth quarter of 2012 reckoned without these deferred tax credits.

The company has provided for tax of $524,812 (net of deferred tax credit) in 2013 against ($142,195) in 2012. In spite of this difference in tax expense, net income after tax increased by 25 per cent from $1,541,317 in 2012 to $1,928,028 in 2013.

Working capital, which is the difference between current assets and current liabilities, increased by 76 per cent from $2,509,278 as at Dec. 31, 2012, to $4,405,910 as at Dec. 31, 2013. Total cash included in working capital on Dec. 31, 2013, was $4,381,137. Total shareholders' equity increased by 71 per cent from $2,839,409 at Dec. 31, 2012, to $4,854,630 at Dec. 31, 2013. This is mainly due to an increase in retained earnings in 2013.

On Oct. 1, 2013, the company signed an exclusive Canadian licence and distribution agreement with a new European partner for a women's health product that has prior approval from Health Canada. The company plans to launch the product in the second quarter of 2014.

Subsequent to year-end, BioSyent in-licensed a new gastrointestinal health product from an existing European partner. This product is approved by Health Canada and is being prepared for launch in fourth-quarter 2014.

The company's consolidated financial statements and management's discussion and analysis will be posted on SEDAR on March 12, 2013.

BioSyent will release a chief executive officer presentation on the fourth-quarter and full-year 2013 financial results at its website.

                              
        CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME               

                         Q4         Q4              Full-year 
                       2013       2012        2013       2012

Revenues         $2,142,835 $1,327,953  $7,799,426 $5,024,154
Cost of goods
sold                448,614    251,401   1,644,266  1,040,136
Total operating
expense           1,075,097    715,315   3,702,320  2,584,896
Net income
before tax          619,124    361,237   2,452,840  1,399,122
Tax (including
deferred tax)        63,580   (142,195)    524,812   (142,195)
Net income after
tax                 555,544    503,432   1,928,028  1,541,317
Net income after
tax % to sales           26         38          25         31

We seek Safe Harbor.